Ahmed Abdelrahman1, Caterina Negroni1, Felix Sahm2, Claire L Adams1, Tadeja Urbanic-Purkart3, Michael Khalil3, Raffaellla Vergura4, Cristina Morelli4, Clemens Oliver Hanemann5. 1. Peninsula Medical School, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth, The John Bull Building, Plymouth Science Park, Research Way, Plymouth, PL6 8BU, UK. 2. Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69126, Heidelberg, Germany. 3. Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036, Graz, Austria. 4. Medical Trials Analysis, Via Ariosto 28, 44100, Ferrara, Italy. 5. Peninsula Medical School, Faculty of Health, Medicine, Dentistry and Human Sciences, University of Plymouth, The John Bull Building, Plymouth Science Park, Research Way, Plymouth, PL6 8BU, UK. oliver.hanemann@plymouth.ac.uk.
Abstract
INTRODUCTION: The current WHO classification and methylation status help predict meningioma recurrence and prognosis. However, up to date, there is no circulating biomarker showing clinical value in meningioma diagnosis or classification. Circulating miRNAs showed the potential to be used as cancer biomarkers in various tumours. This research evaluated specific miRNAs, miR-497 and miR-219, as convenient and efficient predictors of meningioma grades. METHODS: We studied serum and exosomal levels of miR-497 in 74 meningioma samples (WHO grade I = 25, WHO grade II = 25, and WHO grade III = 24) and 53 healthy controls. The serum level of miR-219 was studied in 56 meningioma samples WHO grade I = 22, WHO grade II = 14, and WHO grade III = 20). We used qPCR for miRNA quantification. We also tested two different normalisers, endogenous and external, and evaluated their impact on the diagnostic value of miR-497. RESULTS: The serum and exosomal levels of miR-497 distinguished meningioma from the control samples. Moreover, miR-497 was a suitable identifier for meningioma grade. When we combined miR-497 and miR-219, the efficacy of the combined biomarker was higher than miR-497 or miR-219 when used individually in meningioma classification. Both miR-497 and miR-219 showed a noticeable change with the methylation class of meningioma. CONCLUSION: This study shows that serum miR-497 is an effective and easy-to-measure biomarker for meningioma diagnosis and classification. Moreover, when we combined miR-497 and miR-219, the combined biomarker showed enhanced accuracy in meningioma classification. Furthermore, this is the first study to evaluate the correlation between serum circulating miRNA and the methylation status in meningioma.
INTRODUCTION: The current WHO classification and methylation status help predict meningioma recurrence and prognosis. However, up to date, there is no circulating biomarker showing clinical value in meningioma diagnosis or classification. Circulating miRNAs showed the potential to be used as cancer biomarkers in various tumours. This research evaluated specific miRNAs, miR-497 and miR-219, as convenient and efficient predictors of meningioma grades. METHODS: We studied serum and exosomal levels of miR-497 in 74 meningioma samples (WHO grade I = 25, WHO grade II = 25, and WHO grade III = 24) and 53 healthy controls. The serum level of miR-219 was studied in 56 meningioma samples WHO grade I = 22, WHO grade II = 14, and WHO grade III = 20). We used qPCR for miRNA quantification. We also tested two different normalisers, endogenous and external, and evaluated their impact on the diagnostic value of miR-497. RESULTS: The serum and exosomal levels of miR-497 distinguished meningioma from the control samples. Moreover, miR-497 was a suitable identifier for meningioma grade. When we combined miR-497 and miR-219, the efficacy of the combined biomarker was higher than miR-497 or miR-219 when used individually in meningioma classification. Both miR-497 and miR-219 showed a noticeable change with the methylation class of meningioma. CONCLUSION: This study shows that serum miR-497 is an effective and easy-to-measure biomarker for meningioma diagnosis and classification. Moreover, when we combined miR-497 and miR-219, the combined biomarker showed enhanced accuracy in meningioma classification. Furthermore, this is the first study to evaluate the correlation between serum circulating miRNA and the methylation status in meningioma.
Authors: Felix Sahm; Daniel Schrimpf; Damian Stichel; David T W Jones; Thomas Hielscher; Sebastian Schefzyk; Konstantin Okonechnikov; Christian Koelsche; David E Reuss; David Capper; Dominik Sturm; Hans-Georg Wirsching; Anna Sophie Berghoff; Peter Baumgarten; Annekathrin Kratz; Kristin Huang; Annika K Wefers; Volker Hovestadt; Martin Sill; Hayley P Ellis; Kathreena M Kurian; Ali Fuat Okuducu; Christine Jungk; Katharina Drueschler; Matthias Schick; Melanie Bewerunge-Hudler; Christian Mawrin; Marcel Seiz-Rosenhagen; Ralf Ketter; Matthias Simon; Manfred Westphal; Katrin Lamszus; Albert Becker; Arend Koch; Jens Schittenhelm; Elisabeth J Rushing; V Peter Collins; Stefanie Brehmer; Lukas Chavez; Michael Platten; Daniel Hänggi; Andreas Unterberg; Werner Paulus; Wolfgang Wick; Stefan M Pfister; Michel Mittelbronn; Matthias Preusser; Christel Herold-Mende; Michael Weller; Andreas von Deimling Journal: Lancet Oncol Date: 2017-03-15 Impact factor: 41.316
Authors: Abdurrahman I Islim; Midhun Mohan; Richard D C Moon; Nisaharan Srikandarajah; Samantha J Mills; Andrew R Brodbelt; Michael D Jenkinson Journal: J Neurooncol Date: 2019-01-17 Impact factor: 4.130
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029